Literature DB >> 28741234

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Response to Comment.

Virginie Dufrost1, Jessie Risse1,2, Denis Wahl1,2, Stéphane Zuily3,4.   

Abstract

Entities:  

Keywords:  Antiphospholipid antibodies; Antiphospholipid syndrome; Direct oral anticoagulants; Rivaroxaban; Thrombosis; Triple positivity

Mesh：

Substances：

Year:  2017        PMID： 28741234     DOI： 10.1007/s11926-017-0676-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  7 in total

1.  Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study.

Authors:  Vittorio Pengo; Amelia Ruffatti; Cristina Legnani; Sophie Testa; Tiziana Fierro; Francesco Marongiu; Valeria De Micheli; Paolo Gresele; Marta Tonello; Angelo Ghirarduzzi; Elisa Bison; Gentian Denas; Alessandra Banzato; Seena Padayattil Jose; Sabino Iliceto
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

2.  Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban.

Authors:  Maeve P Crowley; Maria J Cuadrado; Beverley J Hunt
Journal:  Thromb Res       Date:  2017-03-08       Impact factor: 3.944

3.  Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.

Authors:  D R J Arachchillage; M Efthymiou; I J Mackie; A S Lawrie; S J Machin; H Cohen
Journal:  Thromb Res       Date:  2014-12-13       Impact factor: 3.944

4.  Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Authors:  Elise S Eerenberg; Pieter W Kamphuisen; Meertien K Sijpkens; Joost C Meijers; Harry R Buller; Marcel Levi
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

5.  The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation.

Authors:  Laura Green; Andrew S Lawrie; Shelain Patel; Fahad Hossain; Andrew Chitolie; Ian J Mackie; Fares S Haddad; Samuel J Machin
Journal:  Br J Haematol       Date:  2010-10-18       Impact factor: 6.998

6.  Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.

Authors:  Stéphane Zuily; Véronique Regnault; Francis Guillemin; Pierre Kaminsky; Anne-Christine Rat; Thomas Lecompte; Denis Wahl
Journal:  Thromb Res       Date:  2013-05-12       Impact factor: 3.944

7.  Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.

Authors:  H Cohen; C J Doré; S Clawson; B J Hunt; D Isenberg; M Khamashta; N Muirhead
Journal:  Lupus       Date:  2015-05-04       Impact factor: 2.911
  7 in total
  1 in total

1.  Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review.

Authors:  Mandana Khodashahi; Zahra Rezaieyazdi; Maryam Sahebari
Journal:  Arch Rheumatol       Date:  2019-12-12       Impact factor: 1.472
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.